Ascentage Pharma Group International – Unsponsored ADR (NASDAQ:AAPG) Sees Large Decrease in Short Interest

Ascentage Pharma Group International – Unsponsored ADR (NASDAQ:AAPG – Get Free Report) was the target of a significant drop in short interest in October. As of October 30th, there was short interest totaling 9,125 shares, a drop of 49.8% from the October 15th total of 18,161 shares. Approximately 0.0% of the shares of the stock are sold short. Based on an average daily trading volume, of 8,875 shares, the days-to-cover ratio is presently 1.0 days.

Ascentage Pharma Group International Stock Performance

Shares of AAPG opened at $14.62 on Monday. Ascentage Pharma Group International has a 12-month low of $13.46 and a 12-month high of $34.50. The business has a 50-day simple moving average of $15.36 and a two-hundred day simple moving average of $19.61. The company has a quick ratio of 1.18, a current ratio of 1.22 and a debt-to-equity ratio of 1.09.

Ascentage Pharma Group International (NASDAQ:AAPG – Get Free Report) last posted its earnings results on Wednesday, August 19th. The company reported ($0.65) EPS for the quarter. The business had revenue of $22.24 million during the quarter. As a group, analysts predict that Ascentage Pharma Group International will post -2.43 EPS for the current year.

Wall Street Analysts Forecast Growth

Several brokerages have commented on AAPG. JPMorgan Chase & Co. lowered their target price on Ascentage Pharma Group International from $46.00 to $33.00 and set an “overweight” rating for the company in a research note on Thursday, October 8th. BTIG Research restated a “buy” rating and issued a $48.00 price target on shares of Ascentage Pharma Group International in a research note on Friday, August 21st. Citizens Jmp began coverage on shares of Ascentage Pharma Group International in a research note on Tuesday, October 13th. They issued a “market outperform” rating and a $35.00 price target on the stock. Citigroup assumed coverage on shares of Ascentage Pharma Group International in a report on Wednesday, October 14th. They set a “buy” rating and a $46.00 price target on the stock. Finally, William Blair initiated coverage on shares of Ascentage Pharma Group International in a research report on Friday, October 16th. They set an “outperform” rating for the company. Two investment analysts have rated the stock with a Strong Buy rating and eleven have issued a Buy rating to the company. According to data from MarketBeat.com, the stock currently has a consensus rating of “Buy” and an average price target of $43.44.

Check Out Our Latest Report on Ascentage Pharma Group International

About Ascentage Pharma Group International

(Get Free Report)

Ascentage Pharma Group International is a commercial-stage biopharmaceutical company focused on developing and commercializing treatments for cancer and other serious diseases. Its research focuses on therapies that target mechanisms involved in programmed cell death, or apoptosis, to help prevent cancer cells from surviving and multiplying. The company’s two approved oncology drugs in China are olverembatinib, used to treat certain forms of leukemia, and lisaftoclax (APG-2575), a BCL-2 inhibitor approved for certain patients with chronic lymphocytic leukemia and small lymphocytic lymphoma.

See Also

Receive News & Ratings for Ascentage Pharma Group International Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ascentage Pharma Group International and related companies with MarketBeat.com's FREE daily email newsletter.